Comparative study on anticoagulation, bleeding risk after total knee arthroplasty and total hip arthroplasty with rivaroxaban

Objective To evaluate the efficacy and safety of rivaroxaban on the prevention of deep vein thrombosis(DVT) after total knee arthroplasty and total hip replacement. Methods From February 2014 to January 2016, 112 patients with unilateral knee hip replacement were selected and divided into treatment group and control group using a random number table, 56 cases in each group. All patients were operated according to the standard department of orthopedics operation, and the operation was completed. The observation group was treated with rivaroxaban 12 h after surgery, and the control group was treated with subcutaneous injection of low molecular weight heparin 12 h after surgery. The incidence of DVT and the changes of coagulation function were compared between the two groups. Results There was no significant difference in the incidence of DVT between the two groups (3.6% vs 1.8%, P=0.582). The difference of PT, APTT, D-Dimer between the two groups second days and tenth days after operation had no significant (P>0.05). No obvious adverse reactions were found in the two groups. Conclusions Rivaroxaban and low molecular weight heparin have similar efficacy and safety. Application of rivaroxaban is more convenient. Key words: Rivaroxaban; Low molecular weight heparin; Joint replacement